Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease

Tiotropium resulted in a higher FEV₁ than placebo at 24 months and ameliorated the annual decline in the FEV₁ after bronchodilator use in patients with COPD of GOLD stage 1 or 2. (Funded by Boehringer Ingelheim and others; Tie-COPD ClinicalTrials.gov number, NCT01455129 .).